Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.
Colorectal Cancer
DRUG: Vemurafenib|DRUG: Cetuximab
Objective Response Rate(ORR), Evaluation of tumor burden based on RECIST criteria every 3 cycles(each cycle is 14 days), ORR is the proportion of patients with reduction in tumor burden of a predefined amount, including complete response and partial response., up to 55 months
Disease Control Rate (DCR), Evaluation of tumor burden based on RECIST criteria every 3 cycles(each cycle is 14 days), and DCR is the proportion of patients with reduction in tumor burden of a predefined amount, including complete response, partial response and stable disease, up to 55 months|Progression-free survival, Evaluation of tumor burden based on RECIST criteria until first documented progress through study completion, an average of 6 weeks, Time from treatment beginning until the date of first documented progression, assessed up to 55 months|Overall survival, From date of treatment beginning until the date of death from any cause, through study completion, an average of 6 weeks, Time from treatment beginning until date of death from any cause, assessed up to 55 months|adverse events, Incidence of Treatment-related adverse Events, Through study completion, an average of 4 weeks
This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.